Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD. A series of preclinical studies revealed that MR is overactivated under diabetic conditions, resulting in promoting inflamma...

Full description

Bibliographic Details
Main Authors:	Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Series:	Frontiers in Pharmacology
Subjects:	diabetic kidney disease diabetic nephropathy aldosterone mineralocorticoid receptor (MR) mineralocorticoid receptor antagonist (MRA)
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.754239/full

Similar Items

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
by: Wiktoria Baran, et al.
Published: (2021-09-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
by: Yuta Tezuka, et al.
Published: (2021-03-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019-12-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review
by: Xurong Mai, et al.
Published: (2022-11-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
by: Dong-Lim Kim, et al.
Published: (2023-02-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013-10-01)

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
by: Eqerem Hasani, et al.
Published: (2022-01-01)

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
by: Yichuan Wu, et al.
Published: (2022-09-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
by: Luo Shi, et al.
Published: (2019-11-01)

Mineralocorticoid Receptor Activation in Vascular Insulin Resistance and Dysfunction
by: Aderonke E. Igbekele, et al.
Published: (2022-08-01)

Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease
by: Shinji Hagiwara, et al.
Published: (2024-01-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
by: Sho Suzuki, et al.
Published: (2020-10-01)

Eight weeks of treatment with mineralocorticoid receptor blockade does not alter vascular function in individuals with and without type 2 diabetes
by: Stine H. Finsen, et al.
Published: (2024-04-01)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
by: Greg H. Tesch, et al.
Published: (2017-05-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

First Evidence of Mineralocorticoid Receptor Gene and Protein Expression in Rat and Human Thyroid Tissues and Cell Cultures
by: Jacopo Manso, et al.
Published: (2024-01-01)

Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
by: Luca Di Lullo, et al.
Published: (2023-06-01)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
by: Ixchel Lima-Posada, et al.
Published: (2023-01-01)

Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease
by: Andrei Niculae, et al.
Published: (2022-03-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Mineralocorticoid Receptor Signaling Contributes to Normal Muscle Repair After Acute Injury
by: J. Spencer Hauck, et al.
Published: (2019-10-01)

Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
by: Jean Kim, et al.
Published: (2022-03-01)

Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood
by: Bruno Griesler, et al.
Published: (2022-10-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
by: Josefin Henrysson, et al.
Published: (2023-02-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses
by: Camila Q. Felipe, et al.
Published: (2022-06-01)

Hyperglycemia Potentiates Prothrombotic Effect of Aldosterone in a Rat Arterial Thrombosis Model
by: Anna Gromotowicz-Poplawska, et al.
Published: (2021-02-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
by: Irene Lucía Ennis, et al.
Published: (2021-01-01)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
by: Asadur Rahman, et al.
Published: (2023-01-01)

Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists
by: V.М. Yerokhovych, et al.
Published: (2023-12-01)

Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research
by: Argen Mamazhakypov, et al.
Published: (2023-01-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
by: Marie Pieronne‐Deperrois, et al.
Published: (2021-06-01)

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
by: Jack R. Jerome, et al.
Published: (2023-01-01)

Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
by: Mohamad El Wardani, et al.
Published: (2023-03-01)